Avidicure BV
- Biotech or pharma, therapeutic R&D
Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality, “AVC-Boosters”, designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology.
AVC-Boosters unlock strong and orchestrated immunological responses, harnessing the full power of both the innate and adaptive immune system.
The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers and ADCs.
Avidicure’s lead product is AVC-S-101, a TROP2-targeting booster that is being developed for non-small cell lung cancer, and multiple other potential indications.
The Company is based in the Netherlands and supported by a syndicate of top-tier investors led by EQT-Life Sciences.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}